Voyager Therapeutics (NASDAQ:VYGR) Stock Rating Upgraded by Truist Financial

Voyager Therapeutics (NASDAQ:VYGR) was upgraded by Truist Financial to a “strong-buy” rating in a note issued to investors on Wednesday,Zacks.com reports.

VYGR has been the topic of a number of other research reports. HC Wainwright restated a “buy” rating and set a $25.00 target price on shares of Voyager Therapeutics in a report on Tuesday, March 17th. Wall Street Zen raised Voyager Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, March 14th. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $16.50.

Voyager Therapeutics Stock Performance

Shares of Voyager Therapeutics stock opened at $4.13 on Wednesday. The firm has a fifty day moving average of $3.91 and a two-hundred day moving average of $4.19. The stock has a market capitalization of $246.14 million, a price-to-earnings ratio of -2.03 and a beta of 1.32. Voyager Therapeutics has a 52 week low of $2.64 and a 52 week high of $5.55.

Voyager Therapeutics (NASDAQ:VYGR) last posted its quarterly earnings results on Monday, March 9th. The company reported ($0.46) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.54) by $0.08. Voyager Therapeutics had a negative return on equity of 51.35% and a negative net margin of 296.53%.The business had revenue of $13.46 million for the quarter, compared to analyst estimates of $10.49 million. As a group, research analysts forecast that Voyager Therapeutics will post -0.91 EPS for the current fiscal year.

Insiders Place Their Bets

In other Voyager Therapeutics news, CEO Alfred Sandrock sold 14,197 shares of Voyager Therapeutics stock in a transaction that occurred on Tuesday, February 24th. The shares were sold at an average price of $3.79, for a total value of $53,806.63. Following the transaction, the chief executive officer owned 484,060 shares of the company’s stock, valued at approximately $1,834,587.40. The trade was a 2.85% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Insiders have sold a total of 49,783 shares of company stock valued at $188,694 over the last 90 days. Insiders own 6.39% of the company’s stock.

Institutional Investors Weigh In On Voyager Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in VYGR. EcoR1 Capital LLC lifted its position in Voyager Therapeutics by 497.2% in the 4th quarter. EcoR1 Capital LLC now owns 4,002,847 shares of the company’s stock valued at $15,731,000 after acquiring an additional 3,332,544 shares in the last quarter. Vanguard Group Inc. increased its holdings in Voyager Therapeutics by 1.3% during the 3rd quarter. Vanguard Group Inc. now owns 3,250,066 shares of the company’s stock worth $15,178,000 after purchasing an additional 40,147 shares in the last quarter. Opaleye Management Inc. bought a new position in Voyager Therapeutics during the 4th quarter worth about $4,704,000. Erste Asset Management GmbH raised its stake in shares of Voyager Therapeutics by 7.0% in the 4th quarter. Erste Asset Management GmbH now owns 1,195,141 shares of the company’s stock valued at $4,718,000 after purchasing an additional 78,348 shares during the period. Finally, Geode Capital Management LLC raised its stake in shares of Voyager Therapeutics by 1.1% in the 2nd quarter. Geode Capital Management LLC now owns 1,116,847 shares of the company’s stock valued at $3,474,000 after purchasing an additional 11,929 shares during the period. 48.03% of the stock is currently owned by institutional investors and hedge funds.

About Voyager Therapeutics

Voyager Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of gene therapies for serious neurological diseases. The company’s core activities center on the design and delivery of engineered adeno-associated viral (AAV) vectors tailored to target cells in the brain and central nervous system. Through its proprietary CapsidMap and VectorMap platforms, Voyager aims to enhance vector potency, specificity and durability to address diseases with high unmet medical need.

The firm’s pipeline includes several AAV-based candidates in preclinical and early clinical development.